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OPCML, a GPI anchored tumor suppressor gene is inacti-
vated by somatic methylation in multiple cancers. We pre-
viously identified this gene by LOH mapping and
demonstrated that it was inactivated by somatic methyla-
tion in 80% of ovarian cancers. Restoring OPCML expres-
sion by stable transfection suppressed in-vitro growth and
in-vivo tumorigenicity. We hypothesized that OPCML
might abrogate growth signaling pathways. In SKOV-3
and PEO1, ovarian cancer cell lines with no expression of
OPCML, we demonstrated that OPCML negatively regu-
lates a specific repertoire of receptor tyrosine kinases
(RTKs) EPHA2, FGFR1, FGFR3, HER2 and HER4, and
reciprocally, OPCML siRNA and shRNA knockdown in
normal ovarian surface epithelial cells up-regulates these
same RTKs, with no effect on RTKs EPHA10, FGFR2,
FGFR4, EGFR, HER3, VEGFR1 and VEGFR3. shRNA
knockdown shows that loss of OPCML accelerates the
growth of normal ovarian surface epithelial cells in vitro.
Example immunoprecipitation experiments revealed that
OPCML binds to EphA2, FGFR1 and HER2 extracellular
domains with no such interaction to EGFR, thus OPCML
binds directly to RTKS that it negatively regulates.
Cotransfection of ECD less and ECD containing Her2/
Neu shows that the functional tumor suppressor pheno-
type of OPCML is mediated via interaction with the ECD.
We demonstrate that OPCML is located exclusively in the
raft membrane fraction and sequesters RTKs that it binds
to the raft fraction, leading to polyubiquitination and pro-
teosomal degradation via a cav-1 endosomal mechanism
resulting in systems depletion of this specific RTK reper-
toire, that does not occur with RTKs that OPCML does
not bind. Pulse-chase experiments confirm rapid loss of
HER2 in OPCML expressing cells and not in OPCML
deficient cells. We demonstrate that OPCML abrogates
EGF mediated phosphorylation of FGFR1, HER2 and
EGFR and the downstream phosphosignaling of pErk and
pAKT. A recombinant modified OPCML-like protein
without a GPI anchor, signal peptide or glycosylation was
constructed and expressed in E. coli.T h i sr O P C M Lt u m o r
suppressor protein therapeutic caused growth inhibition
by apoptosis in 6/7 ovarian cancer cell lines tested with no
effect on OPCML expressing normal ovarian surface
epithelium by an identical mechanism to the transfected
normal protein. pERk and pAKT inhibition was seen with
functional growth inhibition and increased apoptosis in
rOPCML treated cells. rOPCML was then injected intra-
peritoneally twice weekly in two murine intraperitoneal
models of ovarian cancer (nude mouse A2780 and
SKOV3) and demonstrated profound inhibition of tumour
weight, ascites volume and peritoneal dissemination com-
pared with BSA control. Western analysis from rescued
tumors confirmed that the same mechanism of specific
RTK downregulation was also evident in vivo. In Sum-
mary, the OPCML tumour suppressor mediates its sup-
pressor function by systems level negative regulation of at
least 5 RTKs and a recombinant modified derivative is a
potent tumor suppressor protein therapeutic in-vitro and
in-vivo that recapitulates the in-vitro mechanism.
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